Compare PSFE & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSFE | AQST |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | United Kingdom | United States |
| Employees | 2900 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 475.6M | 529.4M |
| IPO Year | N/A | 2007 |
| Metric | PSFE | AQST |
|---|---|---|
| Price | $6.78 | $4.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $8.69 | ★ $9.00 |
| AVG Volume (30 Days) | 279.9K | ★ 1.4M |
| Earning Date | 05-13-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | $8.15 | $10.08 |
| Revenue Next Year | $6.25 | $49.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $5.95 | $2.94 |
| 52 Week High | $15.02 | $7.55 |
| Indicator | PSFE | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 39.21 | 69.80 |
| Support Level | $6.64 | $3.74 |
| Resistance Level | $8.01 | $5.02 |
| Average True Range (ATR) | 0.39 | 0.18 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 10.32 | 96.64 |
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company's reportable segments are Merchant Solutions and Digital Wallets. The Merchant Solutions segment, which derives maximum revenue, services markets in North America, Canada and Europe. The Digital Wallets segment services markets in Europe, UK, North America and Latin America. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.